WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Bristol-Myers Squibb

Bristol-Myers SquibbBristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

www.bms.com.

Bristol-Myers Squibb RSS Channel

Filters
List of articles in category Bristol-Myers Squibb
Title Published Date
Bristol-Myers Squibb Foundation to Bridge Gaps in Hepatitis C Awareness, Prevention and Care 18 February 2009
Strong Fourth Quarter Supports Excellent 2008 for Bristol-Myers Squibb 28 January 2009
Bristol-Myers Squibb and Pfizer Provide Update on Apixaban Clinical Development Program 28 August 2008
Bristol-Myers Squibb and PDL BioPharma Enter Global Alliance 20 August 2008
Bristol-Myers Squibb Pharma EEIG withdraws its marketing authorisation application for DuoCover 28 May 2008
Celebrity Chef Offers Recipes and Shortcuts in the Kitchen to People with Rheumatoid Arthritis 28 February 2008
Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and 2007 01 February 2008
Avista Capital Partners Completes Acquisition of Bristol-Myers Squibb Medical Imaging 09 January 2008
European Commission Approves ATRIPLA® 18 December 2007
Avista Capital Partners to Acquire Bristol-Myers Squibb Medical Imaging for $525 Million 18 December 2007
Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance - ATRIPLA® 13 December 2007
World Aids Day Campaign to Shine a Light of Hope on the HIV/AIDS Epidemic in the United States 28 November 2007
Bristol-Myers Squibb Company Reports Financial Results 27 October 2007
Bristol-Myers Squibb to Announce Results for the Third Quarter of 2007 on October 25 15 October 2007
Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation 29 September 2007
Bristol-Myers Squibb to Acquire Adnexus Therapeutics 25 September 2007
ERBITUX® Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 12 September 2007
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End

Business & Industry

  • CPHI Pharma Awards open to global innovators, scientists, entrepreneurs and social leaders
  • Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform
  • BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
  • Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma
  • AstraZeneca launches call for entries to the 2023 global R&D Postdoctoral Challenge

Research & Development

  • 'Biohybrid' device could restore function in paralysed limbs
  • Scientists use tardigrade proteins for human health breakthrough
  • DNA treatment could delay paralysis that strikes nearly all patients with ALS
  • Scientists reveal a potential new approach to treating liver cancer
  • Normalizing tumor blood vessels may improve immunotherapy against brain cancer
  • Engineered bacteria find tumors, then alert the authorities
  • First nasal monoclonal antibody treatment for COVID-19 shows promise for treating virus, other diseases

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  • FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
  1. You are here:  
  2. Home
  3. Bristol-Myers Squibb

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.